Novel formulation of cytarabine and daunorubicin: A new hope in AML treatment

被引：17

作者：

Raut, Lalit S. ^{[1
]}

机构：

[1] Vancouver Gen Hosp, Dept Med, Leukemia BMT Div, Vancouver, BC, Canada

来源：

SOUTH ASIAN JOURNAL OF CANCER | 2015年 / 4卷 / 01期

关键词：

CPX-351; cytarabine; daunorubicin; Acute myeloid leukemia; liposomes;

D O I：

10.4103/2278-330X.149950

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Acute myeloid leukemia (AML) treatment has always been a challenge to the treating physician. Continuous efforts are being made to improve treatment outcomes in AML. CPX-351 is a pharmacologic advancement in this direction. It is a liposomal fixed drug combination of cytarabine and daunorubicin. Early studies indicate that it will play a big role in AML treatment. This is a short review about this drug.

引用

页码：38 / 40

页数：3

共 18 条

[1] QUANTITATIVE-ANALYSIS OF DOSE-EFFECT RELATIONSHIPS - THE COMBINED EFFECTS OF MULTIPLE-DRUGS OR ENZYME-INHIBITORS [J].

CHOU, TC ;

TALALAY, P .

ADVANCES IN ENZYME REGULATION, 1984, 22 :27-55

[2]

Cortes JE, PHASE 2 B MULTICENTE

[3]

Feldman E, 2013, J CLIN ONCOL, V31, P15

[4]

Feldman E, 2009, HAEMATOLOGICA, V94, P1

[5] First-In-Man Study of CPX-351: A Liposomal Carrier Containing Cytarabine and Daunorubicin in a Fixed 5:1 Molar Ratio for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia [J].

Feldman, Eric J. ;

Lancet, Jeffrey E. ;

Kolitz, Jonathan E. ;

Ritchie, Ellen K. ;

Roboz, Gail J. ;

List, Alan F. ;

Allen, Steven L. ;

Asatiani, Ekatherine ;

Mayer, Lawrence D. ;

Swenson, Christine ;

Louie, Arthur C. .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (08) :979-985

[6]

Gergis U, 2011, BLOOD, V118, P1306

[7]

Goldberg S, 2012, J CLIN ONCOL, V30, P15

[8]

Harasym T, 2009, HAEMATOLOGICA, V94, P1

[9]

Lancet J, 2009, BLOOD, V114

[10]

Lancet J, 2010, J CLIN ONCOL, V28

← 1 2 →